Calithera BioSciences Inc. achieved the pharmacokinetic and pharmacodynamic goals for its cancer drug CB-1158, entitling the company to a $12 million milestone payment from Incyte Corp. under a collaboration agreement announced earlier this year.

Calithera BioSciences is entitled to receive up to $750 million in milestone payments as a result of the collaboration. CB-1158 is being studied in a monotherapy dose escalation clinical trial and also in combination with anti-PD-1 therapy for the treatment of cancer.

Pharmacokinetics is the study of the action of drugs in the body, while pharmacodynamics is the study of the biochemical and physiological effects of drugs on the body.